Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHARLOTTE-PAIGE ROLLE

Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease

NPI
1023338878
CMS profile
876229
Location
ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$112,875.49

73 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
ViiV Healthcare Company $77,901.82 43
Gilead Sciences, Inc. $27,144.42 28
GlaxoSmithKline, LLC. $7,800.00 1
Merck Sharp & Dohme LLC $29.25 1

Page 2 of 2; records 51–73 of 73 matching records. This page contains 23 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHARLOTTE-PAIGE ROLLE

NPI 1023338878 · CMS profile ID 876229

Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease

ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–73 of 73 matching records. This page contains 23 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1023338878?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHARLOTTE-PAIGE ROLLE, NPI 1023338878, CMS profile ID 876229. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–73 of 73 matching records. This page contains 23 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023338878?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). CHARLOTTE-PAIGE ROLLE, NPI 1023338878, CMS profile ID 876229. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–73 of 73 matching records. This page contains 23 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023338878?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
CHARLOTTE-PAIGE ROLLE, NPI 1023338878, CMS profile ID 876229, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–73 of 73 matching records. This page contains 23 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1023338878?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

73 matching records · $112,875.49 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 73 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–73 of 73.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $31.4304/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234430626 CMS
ViiV Healthcare Company $1,300.0004/29/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1189532274 CMS
ViiV Healthcare Company $1,300.0004/29/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1189541647 CMS
ViiV Healthcare Company $1,300.0004/29/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1189631639 CMS
ViiV Healthcare Company $22.9404/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189617562 CMS
ViiV Healthcare Company $2,600.0004/22/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1189610609 CMS
Gilead Sciences, Inc. $2,760.0004/21/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1234351532 CMS
Gilead Sciences, Inc. $6,750.0004/21/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234353283 CMS
ViiV Healthcare Company $112.0004/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189587397 CMS
ViiV Healthcare Company $7.8904/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189623224 CMS
ViiV Healthcare Company $111.2504/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189584683 CMS
Gilead Sciences, Inc. $330.4304/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234367724 CMS
Gilead Sciences, Inc. $58.1004/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234372293 CMS
Gilead Sciences, Inc. $59.3304/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234411370 CMS
Gilead Sciences, Inc. $504.9704/03/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234365917 CMS
Gilead Sciences, Inc. $270.0004/03/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234368816 CMS
ViiV Healthcare Company $6,500.0004/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1189587153 CMS
ViiV Healthcare Company $6,500.0004/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1189608151 CMS
Gilead Sciences, Inc. $2,950.0003/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234355918 CMS
ViiV Healthcare Company $119.9503/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189621368 CMS
Gilead Sciences, Inc. $28.4003/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234448589 CMS
ViiV Healthcare Company $1,300.0003/20/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1189539057 CMS
Gilead Sciences, Inc. $31.2903/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234431224 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $82,583.91 196
PY2020 $76,150.38 75
PY2021 $78,104.11 81
PY2022 $56,877.18 66
PY2023 $106,902.04 97
PY2024 $105,032.74 108
PY2025 $112,875.49 73

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,122,719.16 90
PY2024 Principal investigator $975,997.55 88
PY2023 Recipient $846.71 8
PY2023 Principal investigator $408,107.74 62
PY2022 Principal investigator $621,107.83 51
PY2021 Principal investigator $739,886.65 46
PY2020 Principal investigator $387,038.95 28
PY2019 Recipient $956.60 10
PY2019 Principal investigator $1,157,679.10 32

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

90 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,006.63 12/18/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202531220
Principal investigator 1 ABBVIE INC. $1,200.00 12/18/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202531230
Principal investigator 1 ABBVIE INC. $2,100.00 12/18/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202531232
Principal investigator 1 Theratechnologies Inc. $276,750.00 12/17/2025 Non-covered Recipient Entity
Orlando Immunology Center
A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States (PROMISE-US) No dispute reported 06/30/2026 1249666548
Principal investigator 1 ABBVIE INC. $1,525.91 12/04/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202527864
Principal investigator 1 ViiV Healthcare Company $34,312.00 12/02/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
CHANGES IN IMMUNOLOGIC PARAMETERS FOLLOWING THE ADDITION OF FOSTEMSAVI No dispute reported 06/30/2026 1190318549
Principal investigator 1 ViiV Healthcare Company $576.45 11/27/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190315905
Principal investigator 1 ViiV Healthcare Company $630.45 11/27/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190316365
Principal investigator 1 ViiV Healthcare Company $576.45 11/27/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190318547
Principal investigator 1 ViiV Healthcare Company $576.45 11/27/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190318877
Principal investigator 1 ViiV Healthcare Company $12,041.27 11/26/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190318449
Principal investigator 1 ViiV Healthcare Company $8,765.03 11/25/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190315713
Principal investigator 1 ViiV Healthcare Company $250.00 11/24/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190315907
Principal investigator 1 ViiV Healthcare Company $710.10 11/24/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318455
Principal investigator 1 ViiV Healthcare Company $506.25 11/24/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318701
Principal investigator 1 ABBVIE INC. $3,357.00 11/17/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202524439
Principal investigator 1 ABBVIE INC. $13,500.00 11/13/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202524123
Principal investigator 1 ViiV Healthcare Company $650.00 11/07/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190316057
Principal investigator 1 ViiV Healthcare Company $400.00 11/07/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318447
Principal investigator 1 ViiV Healthcare Company $100.00 11/07/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318541
Principal investigator 1 ABBVIE INC. $1,382.40 11/04/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202520563
Principal investigator 1 ViiV Healthcare Company $425.25 11/04/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190318879
Principal investigator 1 ViiV Healthcare Company $2,656.11 11/03/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL No dispute reported 06/30/2026 1190318869
Principal investigator 1 ViiV Healthcare Company $12,883.05 10/28/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318553
Principal investigator 1 ViiV Healthcare Company $15,100.00 10/28/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
AN EXPLORATORY PHASE 1B, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO No dispute reported 06/30/2026 1190318865
Principal investigator 1 ABBVIE INC. $3,485.45 10/09/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202515189
Principal investigator 1 ViiV Healthcare Company $14,036.90 09/23/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190318867
Principal investigator 1 ViiV Healthcare Company $17,512.20 09/17/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318453
Principal investigator 1 ViiV Healthcare Company $550.00 09/10/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315915
Principal investigator 1 ViiV Healthcare Company $300.00 09/10/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318703
Principal investigator 1 ABBVIE INC. $481.80 09/04/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202509128
Principal investigator 1 ABBVIE INC. $5,061.16 09/03/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202507617
Principal investigator 1 ViiV Healthcare Company $20,559.15 08/21/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315715
Principal investigator 1 ViiV Healthcare Company $12,329.82 08/18/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190316361
Principal investigator 1 ViiV Healthcare Company $200.00 08/15/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190316061
Principal investigator 1 ViiV Healthcare Company $100.00 08/15/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318871
Principal investigator 1 ViiV Healthcare Company $150.00 08/14/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL No dispute reported 06/30/2026 1190318705
Principal investigator 1 ABBVIE INC. $6,042.27 08/07/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202503937
Principal investigator 1 ViiV Healthcare Company $638.55 08/05/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190315711
Principal investigator 1 ABBVIE INC. $1,861.60 07/31/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202500758
Principal investigator 1 ABBVIE INC. $2,343.40 07/31/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202500774
Principal investigator 1 ABBVIE INC. $1,861.60 07/31/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202500776
Principal investigator 1 ABBVIE INC. $500.00 07/30/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202500516
Principal investigator 1 ABBVIE INC. $4,686.80 07/30/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202500532
Principal investigator 1 ViiV Healthcare Company $10,496.39 07/22/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190318711
Principal investigator 1 ViiV Healthcare Company $20,178.45 07/21/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318875
Principal investigator 1 ViiV Healthcare Company $500.00 07/15/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315911
Principal investigator 1 ViiV Healthcare Company $600.00 07/15/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318445
Principal investigator 1 ViiV Healthcare Company $550.00 07/15/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318555
Principal investigator 1 ViiV Healthcare Company $1,995.00 07/10/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL No dispute reported 06/30/2026 1190315703
Principal investigator 1 ViiV Healthcare Company $1,207.71 07/08/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL No dispute reported 06/30/2026 1190316053
Principal investigator 1 ABBVIE INC. $5,198.18 07/02/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202496321
Principal investigator 1 ViiV Healthcare Company $10,341.48 06/22/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190318543
Principal investigator 1 ABBVIE INC. $10,024.09 06/12/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202491303
Principal investigator 1 ViiV Healthcare Company $14,879.70 06/11/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318707
Principal investigator 1 ABBVIE INC. $7,660.25 06/03/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202489235
Principal investigator 1 ViiV Healthcare Company $23.05 06/03/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190316063
Principal investigator 1 ViiV Healthcare Company $23.05 05/29/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190315717
Principal investigator 1 ViiV Healthcare Company $41,521.95 05/26/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190316369
Principal investigator 1 ViiV Healthcare Company $500.00 05/26/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318551
Principal investigator 1 ViiV Healthcare Company $17,732.33 05/19/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190315913
Principal investigator 1 ViiV Healthcare Company $500.00 05/16/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190315709
Principal investigator 1 Theratechnologies Inc. $2,605.50 05/13/2025 Non-covered Recipient Entity
Orlando Immunology Center
A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States (PROMISE-US) No dispute reported 06/30/2026 1249666543
Principal investigator 1 ViiV Healthcare Company $350.00 05/08/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318699
Principal investigator 1 ViiV Healthcare Company $550.00 05/08/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318873
Principal investigator 1 ABBVIE INC. $18,598.98 05/07/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202482849
Principal investigator 1 ABBVIE INC. $5,272.65 05/07/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202482851
Principal investigator 1 ViiV Healthcare Company $22,569.25 05/06/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
EFFICACY, SAFETY AND TOLERABILITY OF SWITCHING TO DOLUTEGRAVIR/LAMIVUD No dispute reported 06/30/2026 1190318545
Principal investigator 1 ViiV Healthcare Company $51,468.00 05/02/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
CHANGES IN IMMUNOLOGIC PARAMETERS FOLLOWING THE ADDITION OF FOSTEMSAVI No dispute reported 06/30/2026 1190316055
Principal investigator 1 ViiV Healthcare Company $10,341.48 04/28/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190315901
Principal investigator 1 ViiV Healthcare Company $8,738.58 04/28/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2A MULTICENTRE, RANDOMIZED, OPEN-LABEL, TWO-PART ADAPTIVE DESI No dispute reported 06/30/2026 1190318443
Principal investigator 1 ViiV Healthcare Company $44,923.95 04/28/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318713
Principal investigator 1 ABBVIE INC. $5,270.85 04/14/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202476279
Principal investigator 1 ViiV Healthcare Company $4,846.94 04/08/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL No dispute reported 06/30/2026 1190316065
Principal investigator 1 ABBVIE INC. $11,752.77 04/03/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202473658
Principal investigator 1 ViiV Healthcare Company $74,858.00 04/02/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
EFFICACY, SAFETY AND TOLERABILITY OF SWITCHING TO DOLUTEGRAVIR/LAMIVUD No dispute reported 06/30/2026 1190316363
Principal investigator 1 ViiV Healthcare Company $1,445.85 03/21/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315705
Principal investigator 1 ViiV Healthcare Company $12,444.30 03/21/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315707
Principal investigator 1 ViiV Healthcare Company $13,563.66 03/21/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190316051
Principal investigator 1 ViiV Healthcare Company $885.60 03/21/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190316059
Principal investigator 1 ABBVIE INC. $2,929.50 03/20/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER PA
M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202465188
Principal investigator 1 ViiV Healthcare Company $726.30 03/14/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190316371
Principal investigator 1 ABBVIE INC. $17,942.87 03/07/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER PA
M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202461149
Principal investigator 1 ViiV Healthcare Company $13,016.91 02/11/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190318709
Principal investigator 1 ABBVIE INC. $12,658.63 02/06/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER PA
M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202449555
Principal investigator 1 ViiV Healthcare Company $107,615.00 02/04/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
EFFICACY, SAFETY AND TOLERABILITY OF SWITCHING TO DOLUTEGRAVIR/LAMIVUD No dispute reported 06/30/2026 1190318451
Principal investigator 1 Theratechnologies Inc. $2,160.00 02/03/2025 Non-covered Recipient Entity
Orlando Immunology Center
A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States (PROMISE-US) No dispute reported 06/30/2026 1249666540
Principal investigator 1 ViiV Healthcare Company $13,471.33 01/28/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190315903
Principal investigator 1 ViiV Healthcare Company $21,555.53 01/28/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190315909
Principal investigator 1 ViiV Healthcare Company $7,543.60 01/23/2025 Non-covered Recipient Entity
ORLANDO IMMUNOLOGY CENTER
A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL No dispute reported 06/30/2026 1190316367